JP2023524821A5 - - Google Patents
Info
- Publication number
- JP2023524821A5 JP2023524821A5 JP2022567606A JP2022567606A JP2023524821A5 JP 2023524821 A5 JP2023524821 A5 JP 2023524821A5 JP 2022567606 A JP2022567606 A JP 2022567606A JP 2022567606 A JP2022567606 A JP 2022567606A JP 2023524821 A5 JP2023524821 A5 JP 2023524821A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063019853P | 2020-05-04 | 2020-05-04 | |
| US63/019,853 | 2020-05-04 | ||
| US202063093709P | 2020-10-19 | 2020-10-19 | |
| US63/093,709 | 2020-10-19 | ||
| PCT/US2021/030496 WO2021225969A1 (en) | 2020-05-04 | 2021-05-03 | Imino sulfanone inhibitors of enpp1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023524821A JP2023524821A (ja) | 2023-06-13 |
| JP2023524821A5 true JP2023524821A5 (enExample) | 2025-10-08 |
| JP7781774B2 JP7781774B2 (ja) | 2025-12-08 |
Family
ID=76076501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567606A Active JP7781774B2 (ja) | 2020-05-04 | 2021-05-03 | Ｅｎｐｐ１のイミノスルファノン阻害剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11780849B2 (enExample) |
| EP (1) | EP4146344A1 (enExample) |
| JP (1) | JP7781774B2 (enExample) |
| KR (1) | KR20230019431A (enExample) |
| CN (1) | CN115996912A (enExample) |
| AU (1) | AU2021268606A1 (enExample) |
| CA (1) | CA3182410A1 (enExample) |
| IL (1) | IL297929B2 (enExample) |
| MX (1) | MX2022013941A (enExample) |
| TW (1) | TW202208337A (enExample) |
| WO (1) | WO2021225969A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021225969A1 (en) | 2020-05-04 | 2021-11-11 | Volastra Therapeutics, Inc. | Imino sulfanone inhibitors of enpp1 |
| WO2021231726A1 (en) * | 2020-05-14 | 2021-11-18 | Vir Biotechnology, Inc. | Enpp1 modulators and uses thereof |
| TW202214640A (zh) | 2020-06-16 | 2022-04-16 | 美商佛拉斯托醫療公司 | Ｅｎｐｐ１之雜環抑制劑 |
| WO2022091048A1 (en) | 2020-10-30 | 2022-05-05 | Integral Biosciences Private Limited | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (enpp1) inhibitors and uses thereof |
| WO2023086638A1 (en) * | 2021-11-15 | 2023-05-19 | Vir Biotechnology, Inc. | Enpp1 modulators and uses thereof |
| JP2024545511A (ja) * | 2021-12-09 | 2024-12-09 | バラ セラピューティクス，インコーポレイテッド | メニン－ｍｌｌ相互作用の阻害剤 |
| WO2023168240A1 (en) * | 2022-03-02 | 2023-09-07 | The Regents Of The University Of California | Small molecule inhibitors of enpp1 |
| EP4514331A1 (en) | 2022-04-29 | 2025-03-05 | Petragen, Inc. | Inhibitors of enpp1 and modulation of bone growth |
| WO2023225001A1 (en) * | 2022-05-16 | 2023-11-23 | Vir Biotechnology, Inc. | Naphthyridine based enpp1 modulators and uses thereof |
| WO2024028727A1 (en) * | 2022-08-01 | 2024-02-08 | Sravathi Ai Technology Private Limited | Novel ectonucleotide pyrophosphatase / phosphodiesterase 1 (enpp-1) inhibitors and uses thereof |
| WO2024127343A1 (en) * | 2022-12-16 | 2024-06-20 | Sravathi Ai Technology Private Limited | Inhibitors of ectonucleotide pyrophosphatase / phosphodiesterase 1 (enpp-1) |
| WO2025207514A1 (en) * | 2024-03-25 | 2025-10-02 | Riboscience Llc | Bicyclic heteroaryl sulfanediimine derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE904346A1 (en) | 1989-12-04 | 1991-06-05 | Searle & Co | IMIDAZO[1,2-a]PYRIDINYLALKYL COMPOUNDS FOR TREATMENT OF¹NEUROTOXIC INJURY |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| KR100477070B1 (ko) | 1994-03-25 | 2006-04-21 | 이소테크니카 인코포레이티드 | 중수소화작용에의한의약품의효능강화법 |
| NZ536114A (en) * | 2002-03-30 | 2007-11-30 | Boehringer Ingelheim Pharma | 4-(N-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors |
| EP2003132B1 (en) | 2006-04-03 | 2014-03-05 | Astellas Pharma Inc. | Oxadiazole derivatives as S1P1 agonists |
| WO2012032513A1 (en) | 2010-09-07 | 2012-03-15 | Bar-Ilan University | Boranophosphate derivatives for the treatment of osteoarthritis |
| US11179500B2 (en) | 2011-02-24 | 2021-11-23 | Emory University | JAB1 inhibitory compositions for ossification and methods related thereto |
| WO2013132489A1 (en) | 2012-03-05 | 2013-09-12 | Bar-Ilan University | Nucleoside 5'-phosphorothioate analogues and uses thereof |
| WO2014134772A1 (en) | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| EP3226867A4 (en) | 2014-12-05 | 2018-05-09 | Subramaniam Ananthan | Heterocyclic compounds as biogenic amine transport modulators |
| EP3246028A1 (en) | 2016-05-18 | 2017-11-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinoline compounds for increasing insuline release |
| CA3047579A1 (en) | 2016-12-22 | 2018-06-28 | Abbvie Inc. | Compositions and methods of enhancing or augmenting type i ifn production |
| AU2018325445A1 (en) * | 2017-08-31 | 2020-03-19 | Abbvie Inc. | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP-1) inhibitors and uses thereof |
| EA202090595A1 (ru) | 2017-09-08 | 2020-06-29 | Дзе Борд Оф Трастиз Оф Дзе Лелэнд Стэнфорд Джуниор Юниверсити | Ингибиторы enpp1 и способы модуляции иммунного ответа |
| US20190201423A1 (en) | 2017-11-17 | 2019-07-04 | The Regents Of The University Of California | Inhibitors of enpp1 and methods of using same |
| CA3087925A1 (en) | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
| WO2019177971A1 (en) | 2018-03-12 | 2019-09-19 | Mavupharma, Inc. | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof |
| US20190282703A1 (en) | 2018-03-13 | 2019-09-19 | Mavupharma, Inc. | Ectonucleotide pyrophosphatase-phosphodiesterase (enpp) conjugates and uses thereof |
| WO2019191504A1 (en) | 2018-03-30 | 2019-10-03 | Mavupharma, Inc. | Ectonucleotide pyrophosphate-phosphodiesterase (enpp) conjugates and uses thereof |
| JP2020015670A (ja) | 2018-07-23 | 2020-01-30 | 公立大学法人名古屋市立大学 | Ｅｎｐｐ１阻害剤及びその用途 |
| AU2019323035B2 (en) | 2018-08-17 | 2024-11-07 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Pyrazine compounds and uses thereof |
| US20220056052A1 (en) | 2018-12-28 | 2022-02-24 | Riboscience Llc | Quinazoline derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors |
| MX2021009269A (es) | 2019-02-01 | 2021-08-24 | Univ Leland Stanford Junior | Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria. |
| WO2020190912A1 (en) | 2019-03-19 | 2020-09-24 | Stingray Therapeutics, Inc. | Quinoline and quinazoline compounds and methods of use thereof |
| WO2021061803A1 (en) | 2019-09-23 | 2021-04-01 | Nanjing Zhengxiang Pharmaceuticals Co., Ltd. | Phosphodiesterase inhibitors and use |
| WO2021225969A1 (en) | 2020-05-04 | 2021-11-11 | Volastra Therapeutics, Inc. | Imino sulfanone inhibitors of enpp1 |
| WO2021231726A1 (en) | 2020-05-14 | 2021-11-18 | Vir Biotechnology, Inc. | Enpp1 modulators and uses thereof |
| TW202214640A (zh) | 2020-06-16 | 2022-04-16 | 美商佛拉斯托醫療公司 | Ｅｎｐｐ１之雜環抑制劑 |
-
2021
- 2021-05-03 WO PCT/US2021/030496 patent/WO2021225969A1/en not_active Ceased
- 2021-05-03 TW TW110115908A patent/TW202208337A/zh unknown
- 2021-05-03 IL IL297929A patent/IL297929B2/en unknown
- 2021-05-03 CN CN202180045961.2A patent/CN115996912A/zh active Pending
- 2021-05-03 KR KR1020227042614A patent/KR20230019431A/ko active Pending
- 2021-05-03 MX MX2022013941A patent/MX2022013941A/es unknown
- 2021-05-03 CA CA3182410A patent/CA3182410A1/en active Pending
- 2021-05-03 JP JP2022567606A patent/JP7781774B2/ja active Active
- 2021-05-03 AU AU2021268606A patent/AU2021268606A1/en active Pending
- 2021-05-03 EP EP21727704.5A patent/EP4146344A1/en not_active Withdrawn
- 2021-05-03 US US17/306,690 patent/US11780849B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011529918A5 (enExample) | ||
| JP2013010792A5 (enExample) | ||
| JP2013502430A5 (enExample) | ||
| JP2019524861A (ja) | グアニジノ基で置換された縮合［１，２］イミダゾ［４，５−ｃ］環状化合物 | |
| JP2017531038A5 (enExample) | ||
| JP2017523169A5 (enExample) | ||
| RU2005110061A (ru) | Замещенные пиперазины, (1,4)-диазепины и 2,5-диазабицикло(2,2,1)гептаны в качестве н1-и/или н3-антагонистов гистамина или обратных н3-антагонистов гистамина | |
| EP2423207A3 (en) | 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors | |
| RU2012112050A (ru) | Производные дигидроптеридинона, способ их получения и фармацевтическое применение | |
| RU2014113548A (ru) | Нейроактивные стероиды, композиции и их применения | |
| JP2020510010A5 (enExample) | ||
| RU2008119692A (ru) | Новые 1-азабициклоалкилпроизводные для лечения психических растройств | |
| JP2005519932A5 (enExample) | ||
| JP2022514385A5 (enExample) | ||
| JP2005502621A5 (enExample) | ||
| JP2008526999A5 (enExample) | ||
| JP2017524733A5 (enExample) | ||
| JP2022522694A5 (enExample) | ||
| JP2007507494A5 (enExample) | ||
| RU2016150326A (ru) | Производные изоиндолина для применения в лечении вирусной инфекции | |
| JP2020511536A5 (enExample) | ||
| JP2011518168A5 (enExample) | ||
| JP2019533007A5 (enExample) | ||
| RU2007106930A (ru) | Производные хиназолина | |
| AR065297A1 (es) | Formulaciones biodisponibles de compuestos heterociclicos |